Skip to main content

Combination Type 2 Diabetes Pill Approved in Europe


July 27, 2012 — The European Commission has approved the combination pill containing the dipeptidyl peptidase-4 inhibitor linagliptin and metformin hydrochloride for the treatment of adults with type 2 diabetes, alongside diet and exercise. The approval follows a favorable recommendation by the European Medicines Agency in May.
The linagliptin/metformin combination sold in Europe as Jentadueto (Boehringer Ingelheim Pharmaceuticals, Inc, and Eli Lilly & Co) provides a single-tablet option that is taken twice daily.
It is intended for patients with type 2 diabetes that is inadequately controlled on their maximal tolerated dose of metformin alone, metformin plus a sulfonylurea, or those already being treated with the combination of linagliptin and metformin. It can be used alone or in combination with a sulfonylurea.
As previously reported by Medscape Medical News, the linagliptin/metformin combination was approved by the US Food and Drug Administration earlier this year.
In a 24-week, randomized, double-blind, placebo-controlled study involving 791 adults with type 2 diabetes inadequately managed with diet and exercise, 2.5 mg linagliptin/1000 mg metformin led to mean reductions in hemoglobin A1c levels of 1.7 percentage points. Statistically significant reductions in fasting plasma glucose (FPG) of −60 mg/dL were also seen.
In clinical studies, linagliptin/metformin did not cause any significant change in body weight.
Adverse reactions were uncommon in clinical studies. Gastrointestinal disorders occurred most often during the initiation period and tended to resolve spontaneously. A comparable rate of diarrhea was reported with linagliptin/metformin treatment vs metformin plus placebo.
Hypoglycemia was more commonly reported in patients treated with the combination of linagliptin/metformin and a sulfonylurea compared with those treated with the combination of placebo, metformin, and a sulfonylurea.
The linagliptin/metformin combination pill is not indicated for patients with type 1 diabetes or those who have diabetic ketoacidosis. It has not been studied in combination with insulin.
Linagliptin/metformin combination tablets will be made available in the following twice-daily doses in Europe: 2.5 mg linagliptin/850 mg metformin tablets and 2.5 mg linagliptin/1000 mg metformin tablets.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Obama Renominates Tavenner to Be CMS Chief

President Barack Obama yesterday renominated Marilyn Tavenner, the acting administrator of the Centers for Medicare & Medicaid Services (CMS), to serve in that post without the caveat of "acting" attached to it. If the Senate approves her nomination, Tavenner will be the first confirmed, full-fledged CMS administrator since Mark McClellan, MD, PhD, stepped down from that position in October 2006, during the George W. Bush administration. Dr. McClellan's successors either were acting administrators or, in the case of Donald Berwick, MD, who was Tavenner's immediate predecessor, a recess appointment. As illustrated by Dr. Berwick's  CMS history , Senate confirmation can be tough to get when one party has enough votes to filibuster and otherwise stymie a nomination by an opposing party's president. That was the case when Obama nominated Dr. Berwick, whom Senate Republicans portrayed as an advocate of healthcare rationing, a characterization denied by t...
Post a Comment
Read more

Secondary Prevention: Clinical Approaches to Managing the Higher-Risk Patient with Heart Disease

INCIDENCE/PREVALENCE/BURDENS ASSOCIATED WITH CARDIOVASCULAR DISEASE (CVD) The prevention of an initial and recurrent cardiovascular event and other complications, such as diabetes and kidney failure [also known as end-stage renal disease (ESRD) or chronic kidney disease (CKD) stage 5] is an important goal in patients with a history of CVD. Each year, approximately 185,000 Americans suffer a recurrent stroke, approximately 470,000 will have a recurrent coronary attack, and an estimated 325,000 will suffer a recurrent myocardial infarction. [1]  Secondary prevention strategies offer the opportunity to prevent further complications and improve outcomes by early detection and management of common comorbidities. The burden on public health and the costs associated with chronic illnesses such as CVD, CKD, and diabetes remain high. An estimated 82.6 million American adults (1 in 3) have 1 or more types of CVD. [1]  Heart failure is the fastest-growing clinical cardiac disease ...
Post a Comment
Read more